Introduction to Ribociclib/Ribociclib manufacturers and listed companies

Ribociclib, trade name Kisqali, is an oral targeted anti-cancer drug developed and produced by Novartis. The drug is a CDK4/6 inhibitor and is mainly used to treat patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. As a leading global pharmaceutical company, Novartis focuses on the fields of diabetes, oncology and biopharmaceuticals. Riboxiclib is an important breakthrough for Novartis in the field of oncology treatment.

Riboxiclib was approved for marketing by the US FDA in 2017, and was subsequently approved by the European Medicines Agency (EMA) and regulatory agencies in other countries, making it one of the important CDK4/6 inhibitors currently on the international market. In addition to Riboxiclib, Novartis also has a number of blockbuster products in the fields of oncology and diabetes, and continues to promote the research and development of innovative drugs. Riboxiclib has been widely used clinically after its launch, especially in combination with endocrine therapy, showing significant efficacy and improving the progression-free survival of patients.

In recent years, Novartis has continuously increased its investment in the field of oncology. The success of Riboxiclib marks its important achievement in the research and development of anti-cancer drugs and further consolidates its leading position in the global pharmaceutical market. In summary, Riboxiclib was developed and marketed by Novartis, a world-renowned pharmaceutical company. With its strong scientific research strength and complete industrial chain support, the company has provided a solid guarantee for the widespread clinical application and marketing of Riboxil, and promoted the treatment progress of patients with hormone receptor-positive advanced breast cancer.

Reference materials:https://us.kisqali.com/